Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
SHORT INTEREST
688.73K 09/30/19
P/E Current
-0.77
P/E Ratio (with extraordinary items)
-0.66
Average Recommendation: BUY
Average Target Price: 11.00
SHORT INTEREST
688.73K 09/30/19
P/E Current
-0.77
P/E Ratio (with extraordinary items)
-0.66
Average Recommendation: BUY
Average Target Price: 11.00
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media